The Medical Letter on Drugs and Therapeutics
Rivaroxaban (Xarelto) - A New Oral Anticoagulant
The full article is available to subscribers Subscriber Login   

The FDA has approved rivaroxaban (Xarelto – Janssen), an oral direct factor Xa inhibitor, for prevention of deep vein thrombosis (DVT) in patients undergoing knee or hip replacement surgery.

CLINICAL STUDIES — A pooled analysis of four randomized, double-blind trials (the RECORD studies1-4) in a total of 12,729 patients undergoing hip or knee arthroplasty found that a composite endpoint of symptomatic venous thromboembolism (VTE) or death occurred in 0.5% of patients taking rivaroxaban 10 mg once daily and in 1% of patients taking the low-molecular weight heparin enoxaparin 40 mg once or 30 mg twice daily, a significant difference. Major bleeding occurred in 0.3% of patients treated with rivaroxaban and in 0.2% of those receiving enoxaparin. Major plus non-major clinically relevant bleeding occurred in 2.8% vs. 2.5%, and any bleeding occurred in 6.6% vs. 6.2%. None ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Rivaroxaban (Xarelto) - A New Oral Anticoagulant
Article code: 1371b
 Electronic, downloadable article - $25